Metronomic Chemotherapy With Anti-angiogenic Effect as Maintenance Treatment for Metastatic Colorectal Carcinoma Following Response to FOLFIRI+Bevacizumab: Clinical and Laboratory Studies
At entry to the research protocol the up-till then administered treatment with Intra Venous
FOLFIRI+BEVACIZUMAB will be stopped.Instead, the research oral treatment will be initiated
to be taken daily on an ambulatory basis and under once monthly re-evaluation. If and when
disease progresses the original FOLFIRI+BEVACIZUMAB treatment will be considered for
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Length of progression free survival (PFS), measured in months.
From start of the experimental treatment until the date of first documented progression or date of death of any cause,whichever came first, assessed up to 12 months.
Up to 12 months.
David Loven, MD
Israel: Ministry of Health